Skip to content
Open access

Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study

Nov 2026 · Journal of Clinical Medicine · Vol 15, pp. 8568 · 0 citations · 18 references

TL;DR

Findings support individualized adjuvant chemotherapy selection and warrant confirmation in larger cohorts with longer follow-up, particularly regarding the incremental benefit of anthracyclines.

Abstract

Background/Objectives: The optimal adjuvant chemotherapy regimen remains uncertain for some patients with hormone receptor (HR)-positive/HER2-negative early breast cancer, particularly regarding the incremental benefit of anthracyclines. We compared real-world outcomes with docetaxel-plus-cyclophosphamide (TC) and anthracycline–taxane chemotherapy. Methods: This retrospective single-center cohort included patients with stage I–III HR-positive/HER2-negative breast cancer who underwent surgery and received adjuvant TC or anthracycline–taxane chemotherapy between 2019 and 2025. Patients receiving neoadjuvant systemic therapy were excluded. Disease-free survival (DFS) was the primary outcome and overall survival (OS) the secondary outcome. Propensity score overlap weighting adjusted for measured baseline differences was used; the absolute difference in weighted 3-year DFS was the primary adjusted measure. Results: Among 361 patients, 201 received TC and 160 anthracycline–taxane chemotherapy. The anthracycline–taxane group had higher baseline clinicopathologic risk. Median follow-up was 39.0 months. Twelve DFS events occurred (TC, n = 3; anthracycline–taxane, n = 9). Unadjusted 3-year DFS was 99.0% versus 96.6% (p = 0.096), and 3-year OS was 99.4% versus 99.1% (p = 0.725). The overlap-weighted analysis included 346 patients and achieved adequate covariate balance. Weighted 3-year DFS was 99.2% with TC and 96.5% with anthracycline–taxane chemotherapy, an absolute difference of 2.68 percentage points (95% CI, −1.81 to 10.03). Sensitivity analysis yielded similar results (2.70 percentage points; 95% CI, −1.76 to 9.87). Conclusions: No statistically significant difference in 3-year DFS was demonstrated after adjustment. Limited events and relatively short follow-up preclude conclusions regarding equivalence or noninferiority. These findings support individualized adjuvant chemotherapy selection and warrant confirmation in larger cohorts with longer follow-up.

Read PDF

Similar papers

Open access 2026

Adjuvant capecitabine in residual triple-negative breast cancer after carboplatin-based neoadjuvant chemotherapy: a real-world cohort

Introduction: Patients with triple-negative breast cancer (TNBC) who do not achieve pathologic complete response (pCR) after neoadjuvant chemotherapy have a worse prognosis. Adjuvant capecitabine has demonstrated benefit in selected populations, but its role after prior carboplatin exposure remains uncertain, particula...

G. Tavares, S. Ramalho, L. Silva et al. · 0 citations
Open access Oct 2026

Impact of Carboplatin on Long-Term Survival after Neoadjuvant Chemotherapy in Non-Metastatic Triple-Negative Breast Cancer: An Algerian Cohort Study

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression. Platinum agents such as carboplatin have been incorporated into neoadjuvant regimens to improve pathological complete response (pCR)...

Samira Merah, Amal Kouchkar, A. Ladjeroud et al. · 0 citations
Open access Oct 2026

Neoadjuvant Versus Adjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer: A National Cancer Database Study

Background/Objectives: While neoadjuvant chemo-immunotherapy has become a standard treatment for patients with early-stage triple-negative breast cancer (TNBC) based on KEYNOTE-522, the trial did not directly compare neoadjuvant with adjuvant chemo-immunotherapy. We compared treatment patterns and survival outcomes bet...

Taiga Komatsu, R. Patel, A. Tiersten · 0 citations
Open access 2026

Pathologic complete response and survival outcomes after carboplatin-based neoadjuvant chemotherapy in triple-negative breast cancer: a real-world cohort

Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a high risk of early relapse. The addition of carboplatin to neoadjuvant chemotherapy increases pathologic complete response (pCR) rates, which are strongly associated with survival outcomes. In the Brazilian pu...

G. Tavares, S. Ramalho, L. Silva et al. · 0 citations
Open access 2026

Predictors of four versus six cycles of adjuvant docetaxel–cyclophosphamide in hormone receptor-positive early breast cancer

Introduction: Docetaxel and cyclophosphamide (TC) are a commonly used anthracycline-free regimen for hormone receptor-positive (HR+) early-stage breast cancer. Although typically administered for four to six cycles, the optimal number remains uncertain. Objective: To identify clinical and pathological factors associat...

W. Lima, Rafaela Lopes da Silva Naves, R. Bonadio et al. · 0 citations
Open access Oct 2026

Race and the neoadjuvant-to-adjuvant pembrolizumab transition for early-stage triple-negative breast cancer in the KEYNOTE-522 era: A TriNetX US Collaborative Network analysis.

238 Background: Pembrolizumab plus chemotherapy is standard neoadjuvant therapy for high-risk early-stage triple-negative breast cancer (TNBC) per KEYNOTE-522. Prior real-world studies have documented Black-White disparities in initial KEYNOTE-522 receipt and regimen tolerability, but the discrete neoadjuvant-t...

Abhinav Vayal-Veettil, J. Hundal, Jame Abraham · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.